Page 2427 - Williams Hematology ( PDFDrive )

2398 Index Index 2399

α-globin chains (Cont.): pathophysiology. See Thalassemias, AMPK (adenosine monophosphate kinase),
in hemoglobin H disease, 1353 pathophysiology 194–195
variants, 751, 778 in pregnancy, 126 Amsacrine
α-globin gene cluster, 728–729, 729f unusual forms, 739 for acute myelogenous leukemia, 1395
α granules, 1818, 1819f, 1843–1845, 1844f, ALPS (autoimmune lymphoproliferative secondary acute myelogenous leukemia
1846–1847t, 1848, 2166 syndrome), 210, 1224, 1575t and, 1407
α-heavy-chain disease, 1806–1809 Alteplase, 403 Amyloid, 1773
chromosomal abnormalities, 1808 for myocardial infarction, 2295 Amyloid light-chain amyloidosis. See
clinical features, 1806–1807 for stroke, 2314, 2314t, 2315 Immunoglobulin light-chain (AL)
course and prognosis, 1809 Alternative pathway of complement, 572, amyloidosis
definition and history, 1806 572f Amyloidoses
differential diagnosis, 1808 Alum, 422 AA (secondary), 1773, 1774t, 1776
epidemiology, 1806 Alvocidib, for chronic lymphocytic leukemia, classification, 1773, 1774t
etiology and pathogenesis, 1806 218 in familial Mediterranean fever, 1006, 1773
gene mutations, 1807, 1807f Alzheimer disease, 1848 immunoglobulin light-chain. See
laboratory features, 1807–1808, 1807f AM (α-chain) allotypes, 1170 Immunoglobulin light-chain (AL)
therapy, 1808–1809 Ambroxol, 1128 amyloidosis
α helix, disruption of, 781 Amenorrhea, history of, 5 inherited forms, 1773, 1774t, 1776,
α integrins. See under Integrin Amifostine, for acute myelogenous leukemia, 1777–1778
α-storage pool deficiency (gray platelet 1404 systemic, 2108
syndrome), 1850, 1853, Amikacin, 386, 387t Amyloid precursor protein (APP), 1848
2054–2055, 2055f Amino acids Anagrelide
α-thalassemia–myelodysplastic syndrome, deletions, unstable hemoglobins and, 781 adverse effects, 1314, 2081
1353 in neutrophils, 935, 935t for chronic myeloproliferative disorders,
α-thalassemias Aminocaproic acid. See ε-aminocaproic acid 2081
α 0 (EACA) for cytoreduction in chronic myelogenous
deletion forms, 748 Aminoglycosides, 384 leukemia, 1450–1451
epidemiology/population genetics, 727, δ-Aminolevulinate dehydratase (ALAD), 894 for essential thrombocythemia, 1313t,
727f δ-Aminolevulinate dehydratase porphyria 1314, 1314t, 2081
laboratory features, 747–748 (ADP), 890t, 891t, 894, 900 for polycythemia vera, 1298t, 1300
molecular basis, 736–737, 737t, 738f δ-Aminolevulinate hydrolase, 894 Anakinra, for Erdheim-Chester disease, 1111
α + δ-Aminolevulinate synthase (ALAS), Anal cancer, 1243
epidemiology/population genetics, 727, 892–894 Anaphylactic reactions, 2375
727f 5-Aminolevulinic acid (ALA), 1686 Anaphylatoxin, 932
laboratory features, 747 δ-Aminolevulinic acid (ALA), 889, 891f, 893f Anaplastic large cell lymphoma (ALCL)
molecular basis, 737–738, 737t, 738f δ-Aminolevulinic acid (ALA) dehydrase, ALK-negative, 1694t, 1695t, 1698, 1699
with α- and β-chain hemoglobin variants, 701t ALK-positive, 1637, 1694t, 1695t,
731 Aminopeptidase N. See CD13 1698–1699
clinical features, 745 Aminopterin (4-aminopteroylglutamic acid) breast implant–associated, 1698
deletional, 771 for acute lymphoblastic leukemia, 1505 chromosomal abnormalities, 185t, 188,
differential diagnosis, 748, 749f mechanism of action, 197 224t, 1499t, 1576–1577
epidemiology/population genetics, megaloblastic anemia and, 605, 606t clinical features, 1698
727–728, 727f Aminopyrine, 996 definition, 1698
haplotype interactions, 739 AML. See Acute myelogenous (myeloid) epidemiology, 1694t, 1698
hemoglobin Bart’s hydrops fetalis leukemia (AML) gene mutations, 1499t
syndrome. See Hemoglobin Bart’s AML1. See RUNX1 (AML1) laboratory features, 1499t, 1598–1599,
hydrops fetalis syndrome AML1-ETO, 225, 240 1599f, 1600f, 1699–1700
hemoglobin H disease. See Hemoglobin H AMLI-3, 926 primary cutaneous. See Primary cutaneous
disease AMML (acute myelomonocytic leukemia), anaplastic large cell lymphoma
hemoglobin variants causing, 778t 180, 1382f, 1387, 1388t, 1390 prognosis, 1695t, 1699
leukemia and, 739 AMN (amnionless), 591, 605 treatment, 1694–1696, 1695t, 1696t, 1699
mental retardation and, 739, 745 Amniotic fluid embolism, 2210 ANCAs (antineutrophil cytoplasmic
minor, 636 Amniotic fluid spectrophotometry, 854 antibodies), 959–960, 2107
molecular basis, 736–739, 737t, Amotosalen, 2388 Ancylostomiasis, 957t
739f AMP deaminase, 701t Anderson disease, 567
myelodysplasia and, 739 Amphotericin B, 385, 387t Androgens

Kaushansky_index_p2393-2506.indd 2398 9/21/15 3:21 PM